Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Challenges in treating pediatric leukemias

Sarah Tasian • 13 Dec 2021
ASH 2021
Leukemia

Sarah Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, provides an overview of remaining barriers in treating pediatric leukemias. Conventional chemotherapy is the standard of care in pediatric patients, and establishing the correct dose whilst minimizing toxicity is an important issue for healthcare practitioners. Dr Tasian additionally highlights the development of immunotherapies for pediatric patients who have relapsed from frontline chemotherapy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Sarah Tasian

1:09
Precision medicine in pediatric ALL
Sarah Tasian • 4 Jun 2023
1:16
Pediatric leukemia at ASCO 2023
Sarah Tasian • 4 Jun 2023
0:54
Clinical responses of pediatric patients with R/R acute leukemia treated with aza/ven
Sarah Tasian • 16 Apr 2023
0:56
Improving therapeutic approaches for patients with Ph-like ALL & the importance of disease biology
Sarah Tasian • 16 Apr 2023

Related Videos

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals